Fintel reports that on November 10, 2025, B of A Securities maintained coverage of Moderna (NasdaqGS:MRNA) with a ...

A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...

With continued investment in mRNA research, Donald Trump could turn the stalemate against cancer into a decisive breakthrough ...

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

That something as simple as a COVID-19 vaccine might improve survival in cancer patients receiving standard immunotherapy has ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Researchers discovered that embryos must clear maternal mRNAs to develop properly. When cleanup fails, it causes aberrant ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the ...

New research found that mRNA vaccines for COVID-19 could enhance cancer treatments and help patients live longer.

All of these questions deserve urgent exploration. Unfortunately, the discovery comes at a particularly difficult moment for ...